Flagship Biosciences

The AI engine Fit Assessment

Beta

Flagship Biosciences leverages machine learning for data analysis, discovers new patterns in biomarker data, and supports drug development, enhancing therapeutic options.

Blurb

Flagship Biosciences delivers comprehensive tissue profiling using our Artificial Intelligence (AI) enabled cTA® pathology platform.

HQ Location

Broomfield (United States)

Founded

2009

Employees

51 - 200

Total funding raised

$20.29M

Funding Status

Venture - Series Unknown, $5.00M, April 16, 2024
Subspaces
  • Biomarker Identification

Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.